ReviewFrontiers in genetics2025
Machine learning tools for deciphering the regulatory logic of enhancers in health and disease.
Review in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcriptional enhancers are DNA regulatory elements that control the levels and spatiotemporal patterns of gene expression during development, homeostasis, and pathophysiological processes. Enhancer identification and characterization at the genome-wide scale rely on their structural characteristics, such as chromatin accessibility, binding of transcription factors and cofactors, activating histone modifications, 3D interactions with other regulatory elements, as well as functional characteristics measured by massively parallel reporter assays and sequence conservation approaches. Recently, machine learning approaches and particularly deep learning models (Enformer, BPNet, DeepSTARR, etc.) allow the prediction of enhancers, the impact of variants on their activity and the inference of transcription factor binding sites, leading, among others, to the construction of the first completely synthetic enhancers. We present the above computational tools and discuss their diverse applications towards cracking the enhancer regulatory code, which could have far-reaching ramifications for uncovering essential regulatory mechanisms and diagnosing and treating diseases. With an emphasis on sepsis, a leading cause of morbidity and mortality in hospitalized patients, we discuss computational approaches to identify sepsis-associated endotypes, circuits, and immune cell states and signatures characteristic of this condition, which could aid in developing novel therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.